Lupin to market Linagliptin for Boehringer Ingelheim under the brand name Ondero and Ondero Met in India
Lupin and Boehringer Ingelheim (BI) have announced a joint strategic alliance for co-marketing linagliptin, a novel Dipeptidylpeptidase-4 (DPP-4) inhibitor in India. BI has a strong presence in the DPP-4 Inhibitors market in India which is growing at 27 per cent.
According to the agreement, Lupin will market and sell linagliptin under a separate brand name Ondero (monotherapy) and Ondero Met (fixed-dose combination with metformin) which will be promoted by Lupin’s 400 strong dedicated diabetes speciality field force. BI will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combination with metformin) through their existing sales force and network.
Ondero tablets (monotherapy) are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus. Ondero Met tablets (fixed-dose combination therapy) are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both linagliptin and metformin is appropriate.
Shakti Chakraborty, Group President, India Region Formulations, Lupin said, “I believe our entry into the high growth DPP-4 Inhibitor market with the launch of Ondero and Ondero Met will not only strengthen our diabetes portfolio but also help us consolidate our position as a market leader and the fastest growing player in the TOP 5 in the anti-diabetes segment.”
Sharad Tyagi, Managing Director, Boehringer Ingelheim India said, “We are pleased to partner with Lupin for the sales and promotion of linagliptin as Lupin has a strong play in the anti-diabetes segment with a robust product portfolio. The partnership is aligned with our commitment towards addressing challenges in treatment of chronic ailments like diabetes by providing broader access to innovative medicines. It is an ideal partnership where BI brings the research and scientific excellence for linagliptin, and Lupin their marketing excellence and brand equity amongst key clinician categories to drive and facilitate product access. Boehringer Ingelheim India will continue to introduce innovative products to address the unmet patients’ needs amidst the growing Indian diabetes epidemic.”
- Advertisement -
Comments are closed.